ImmuPharma PLC Asset Resilience Ratio

Latest as of December 2023: 0.00%

ImmuPharma PLC asset resilience ratio. ImmuPharma PLC (IMM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of ImmuPharma PLC to measure how many days the company can operate on defensive assets alone.

Liquid Assets

GBX-1.00

≈ $-0.00 USD Cash + Short-term Investments

Total Assets

GBX2.72 Million

≈ $331.12 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of ImmuPharma PLC (2016–2022)

Asset resilience ratio of ImmuPharma PLC from 2016 to 2022. This chart shows how ImmuPharma PLC's Asset Resilience Ratio has changed over time. Read IMM liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down ImmuPharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ImmuPharma PLC asset portfolio.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-1.00	-0.0%
Total Liquid Assets	GBX-1.00	0.00%

Asset Resilience Insights

Limited Liquidity: ImmuPharma PLC maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

ImmuPharma PLC Industry Peers by Asset Resilience Ratio

Compare ImmuPharma PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	15.21%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Immunovant Inc NASDAQ:IMVT	Biotechnology	98.50%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Amicus Therapeutics Inc NASDAQ:FOLD	Biotechnology	8.37%

ImmuPharma PLC Asset Resilience Ratio by Year (2016–2022)

ImmuPharma PLC asset resilience ratio by year from 2016 to 2022. The table below shows the annual Asset Resilience Ratio data for ImmuPharma PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-2.08%	GBX-82.56K ≈ $-10.05	GBX3.97 Million ≈ $483.61	+4.68pp
2021-12-31	-6.76%	GBX-405.49K ≈ $-49.34	GBX6.00 Million ≈ $729.76	-5.16pp
2020-12-31	-1.60%	GBX-174.49K ≈ $-21.23	GBX10.92 Million ≈ $1.33K	+12.94pp
2019-12-31	-14.53%	GBX-843.15K ≈ $-102.59	GBX5.80 Million ≈ $705.82	-37.71pp
2016-12-31	23.17%	GBX1.55 Million ≈ $189.18	GBX6.71 Million ≈ $816.39	--

pp = percentage points

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$201.24K

GBX1.65 Billion GBX

Market Cap Rank

#31352 Global

#1016 in UK

Share Price

GBX3.29

Change (1 day)

+9.48%

52-Week Range

GBX3.01 - GBX10.70

All Time High

GBX190.00